Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Wenhui Lou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5820-6843; OpenAlex author ID A5037626265. Sources: OpenAlex.

Their work

Papers
45 (first author 1, last author 20)
Trials
0
Grants
0
Labs led
1
Collaborators
134
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 2 papers · 2017: 3 papers · 2018: 4 papers · 2019: 6 papers · 2020: 5 papers · 2021: 5 papers · 2022: 3 papers · 2023: 3 papers · 2024: 2 papers · 2025: 4 papers · 2026: 4 papers

Papers 45

  1. Pathomics Signature for Prognosis and CA19-9 Interception in Pancreatic Ductal Adenocarcinoma: A Real-Life, Multi-Center Study. Co-author DOI 10.1002/advs.202515952↗
  2. DDR1 sustains ferroptosis resistance in pancreatic ductal adenocarcinoma via SLC40A1-mediated iron homeostasis. Co-author DOI 10.1038/s41388-026-03980-w↗
  3. RASA2 Promotes Pancreatic Cancer Metastasis by Activating TGFβ-Dependent Non-canonical Hedgehog Signaling. Co-author DOI 10.1158/0008-5472.can-26-0333↗
  4. Gut microbiota and pancreatic cancer: tumorigenesis, progression, and clinical applications. Co-author DOI 10.20892/j.issn.2095-3941.2025.0650↗
  5. The Crosstalk with CXCL10-Rich Tumor-Associated Mast Cells Fuels Pancreatic Cancer Progression and Immune Escape. Co-author DOI 10.1002/advs.202417724↗
  6. The Evolutionary Trajectory and Prognostic Value of GITR+ Tregs Reprogramed by Tumor-Intrinsic PD-1/c-MET Signaling in Pancreatic Cancer. Co-author DOI 10.1002/advs.202500806↗
  7. Unveiling circulating targets in pancreatic cancer: Insights from proteogenomic evidence and clinical cohorts. Co-author DOI 10.1016/j.isci.2024.111693↗
  8. Intratumoral IL-33 + CD4 + FoxP3 + regulatory T cell infiltration determines poor clinical outcomes and intensive immunoevasive contexture in patients with pan… Co-author DOI 10.1097/js9.0000000000002733↗
  9. Circulating cell-free DNA methylation-based multi-omics analysis allows early diagnosis of pancreatic ductal adenocarcinoma. Last author DOI 10.1002/1878-0261.13643↗
  10. Poor clinical outcomes and immunoevasive contexture in CD161+CD8+ T cells barren human pancreatic cancer. Co-author DOI 10.1136/jitc-2023-008694↗
  11. Tumor Microenvironment Responsive CD8+ T Cells and Myeloid-Derived Suppressor Cells to Trigger CD73 Inhibitor AB680-Based Synergistic Therapy for Pancreatic Ca… Last author DOI 10.1002/advs.202302498↗
  12. Long-term outcomes of standard versus extended lymphadenectomy in pancreatoduodenectomy for pancreatic ductal adenocarcinoma: A Chinese multi-center prospectiv… First author DOI 10.1016/j.jare.2022.09.011↗
  13. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery… Co-author DOI 10.1016/j.pan.2023.07.005↗
  14. Current status and future perspectives of clinical research in pancreatic cancer: Establishment of evidence by science. Last author DOI 10.1002/jhbp.1045↗
  15. Gene expression profiling reveals the genomic changes caused by MLN4924 and the sensitizing effects of NAPEPLD knockdown in pancreatic cancer. Last author DOI 10.1080/15384101.2021.2014254↗
  16. GFAT1 is highly expressed in cancer stem cells of pancreatic cancer. Co-author DOI 10.21037/atm-22-1946↗
  17. Prognostic value of preoperative glucose to lymphocyte ratio in patients with resected pancreatic cancer. Last author DOI 10.1007/s10147-020-01782-y↗
  18. Lymph Node Metastatic Patterns and Survival Predictors Based on Tumor Size in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1007/s12325-021-01819-2↗
  19. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic c… Co-author DOI 10.1038/s41419-021-04293-4↗
  20. Upregulated circRNA hsa_circ_0071036 promotes tumourigenesis of pancreatic cancer by sponging miR-489 and predicts unfavorable characteristics and prognosis. Last author DOI 10.1080/15384101.2021.1874684↗
  21. Positive Impact of Intraoperative Epidural Ropivacaine Infusion on Oncologic Outcomes in Pancreatic Cancer Patients Undergoing Pancreatectomy: A Retrospective … Co-author DOI 10.7150/jca.57661↗
  22. PRMT1 promotes pancreatic cancer growth and predicts poor prognosis. Last author DOI 10.1007/s13402-019-00435-1↗
  23. Preoperative radiotherapy improves overall survival of pT4 pancreatic ductal adenocarcinoma patients after surgical resection. Last author DOI 10.1093/jjco/hyaa035↗
  24. CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer. Co-author DOI 10.1111/jcmm.15500↗
  25. Current Role of Surgery in Pancreatic Cancer With Synchronous Liver Metastasis. Last author DOI 10.1177/1073274820976593↗
  26. Knockdown EIF3C Suppresses Cell Proliferation and Increases Apoptosis in Pancreatic Cancer Cell. Last author DOI 10.1177/1559325820950061↗
  27. TRAF6 regulates YAP signaling by promoting the ubiquitination and degradation of MST1 in pancreatic cancer. Co-author DOI 10.1007/s10238-018-00543-6↗
  28. Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer. Last author DOI 10.1016/j.yexcr.2019.111543↗
  29. Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score matching analysis. Last author DOI 10.1186/s40880-019-0410-8↗
  30. Downregulated expression of RACK1 results in pancreatic cancer growth and metastasis. Co-author DOI 10.2147/ott.s176101↗
  31. Optimized modification of the eighth edition of AJCC TNM staging system for resected pancreatic ductal adenocarcinoma. Last author DOI 10.2217/fon-2019-0264↗
  32. Consolidative Chemoradiotherapy After Induced Chemotherapy Is an Optimal Regimen for Locally Advanced Pancreatic Cancer. Last author DOI 10.3389/fonc.2019.01543↗
  33. Chk1 inhibitor SCH 900776 enhances the antitumor activity of MLN4924 on pancreatic cancer. Last author DOI 10.1080/15384101.2017.1405194↗
  34. Survival prediction in pancreatic cancer patients with no distant metastasis: a large-scale population-based estimate. Last author DOI 10.2217/fon-2017-0380↗
  35. Lactic dehydrogenase to albumin ratio in prediction of unresectable pancreatic cancer with intervention chemotherapy. Co-author DOI 10.2217/fon-2017-0556↗
  36. Detection of CTCs in portal vein was associated with intrahepatic metastases and prognosis in patients with advanced pancreatic cancer. Co-author DOI 10.7150/jca.23989↗
  37. KRAS/NF-κB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis. Co-author DOI 10.1158/0008-5472.can-16-1898↗
  38. BRSK2 induced by nutrient deprivation promotes Akt activity in pancreatic cancer via downregulation of mTOR activity. Co-author DOI 10.18632/oncotarget.17965↗
  39. Overexpression of miR-135b-5p promotes unfavorable clinical characteristics and poor prognosis via the repression of SFRP4 in pancreatic cancer. Co-author DOI 10.18632/oncotarget.19150↗
  40. Plasma miRNAs Effectively Distinguish Patients With Pancreatic Cancer From Controls: A Multicenter Study. Co-author DOI 10.1097/sla.0000000000001345↗
  41. Plasma microRNA panels to diagnose pancreatic cancer: Results from a multicenter study. Co-author DOI 10.18632/oncotarget.9491↗
  42. TRAF6 is over-expressed in pancreatic cancer and promotes the tumorigenicity of pancreatic cancer cells. Last author DOI 10.1007/s12032-014-0260-9↗
  43. HIF1 contributes to hypoxia-induced pancreatic cancer cells invasion via promoting QSOX1 expression. Last author DOI 10.1159/000354460↗
  44. IRF-2 is over-expressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. Co-author DOI 10.1007/s13277-011-0273-3↗
  45. [Expression of dihydropyrimidine dehydrogenase negatively correlated with the prognosis of pancreatic ductal adenocarcinoma]. Last author PMID 21612699↗

Closest collaborators

The 25 strongest of 134 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wenchuan Wu · 18 shared papers, 2014–2026 · strength 2.53
  2. Ning Pu · 15 shared papers, 2018–2026 · strength 2.46
  3. Hanlin Yin · 13 shared papers, 2020–2026 · strength 2.40
  4. Qiangda Chen · 11 shared papers, 2020–2026 · strength 1.94
  5. Taochen He · 8 shared papers, 2024–2026 · strength 1.72
  6. Tiantao Kuang · 13 shared papers, 2014–2024 · strength 1.46
  7. Dansong Wang · 12 shared papers, 2014–2024 · strength 1.39
  8. Yefei Rong · 12 shared papers, 2012–2024 · strength 1.18
  9. Jun Yu · 6 shared papers, 2019–2026 · strength 0.99
  10. Yaolin Xu · 6 shared papers, 2020–2025 · strength 0.98
  11. Yun Jin · 4 shared papers, 2025–2026 · strength 0.83
  12. Xuefeng Xu · 7 shared papers, 2018–2022 · strength 0.76
  13. Jianang Li · 5 shared papers, 2019–2025 · strength 0.73
  14. Dayong Jin · 7 shared papers, 2012–2022 · strength 0.69
  15. Jiande Han · 3 shared papers, 2024–2025 · strength 0.60
  16. Wenquan Wang · 3 shared papers, 2023–2026 · strength 0.59
  17. Xu Han · 5 shared papers, 2017–2025 · strength 0.58
  18. Joseph R. Habib · 4 shared papers, 2019–2025 · strength 0.58
  19. Huaxiang Xu · 3 shared papers, 2023–2025 · strength 0.56
  20. Yuan Fang · 6 shared papers, 2011–2021 · strength 0.55
  21. Lei Zhang · 3 shared papers, 2022–2023 · strength 0.51
  22. Wentao Zhou · 4 shared papers, 2019–2021 · strength 0.51
  23. Chenye Shi · 4 shared papers, 2013–2025 · strength 0.48
  24. Shanshan Gao · 4 shared papers, 2018–2025 · strength 0.47
  25. Weilin Mao · 3 shared papers, 2019–2024 · strength 0.47

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.